These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29745935)

  • 1. [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.].
    Chantada-Abal V; Chantada-Tirado C; Lamas-Díaz L; Caramés-Masana F; Villegas-Piguave AD; Villar-Vázquez N
    Arch Esp Urol; 2018 May; 71(4):453-457. PubMed ID: 29745935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial.
    Cicione A; Lombardo R; Nacchia A; Franco A; Simone G; Pastore A; Leonardo C; Franco G; Tubaro A; DE Nunzio C
    Minerva Urol Nephrol; 2024 Aug; 76(4):458-466. PubMed ID: 38842053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.
    Witjes JA; v d Meijden AP; Collette L; Sylvester R; Debruyne FM; van Aubel A; Witjes WP
    Urology; 1998 Sep; 52(3):403-10. PubMed ID: 9730451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.
    Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
    Investig Clin Urol; 2020 Jul; 61(4):349-354. PubMed ID: 32665991
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
    Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
    Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
    Shelley MD; Wilt TJ; Court J; Coles B; Kynaston H; Mason MD
    BJU Int; 2004 Mar; 93(4):485-90. PubMed ID: 15008714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Grimberg DC; Dudinec J; Shah A; Inman BA
    Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Morales A
    J Urol; 1999 May; 161(5):1582-3. PubMed ID: 10210415
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
    Ooi WL; Stockler M; Hayne D
    Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
    [No Abstract]   [Full Text] [Related]  

  • 18. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
    BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
    Järvinen R; Kaasinen E; Rintala E; Group TF
    Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
    Lan Y; Liu D; Lin M
    Neoplasma; 2016; 63(6):967-976. PubMed ID: 27596297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.